[
    [
        {
            "time": "2018-01-02",
            "original_text": "Conatus (CNAT) Completes Enrollment in Phase II NASH Study",
            "features": {
                "keywords": [
                    "NASH",
                    "Phase II",
                    "enrollment"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Exelixis (EXEL) Earnings, Revenues Beat Estimates in Q4",
            "features": {
                "keywords": [
                    "earnings",
                    "revenues",
                    "beat estimates",
                    "Q4"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "What Are the Key Growth Drivers for Pfizer in Fiscal 2019?",
            "features": {
                "keywords": [
                    "growth drivers",
                    "Pfizer",
                    "fiscal 2019"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-13",
            "original_text": "Health Care Sector Update for 02/13/2019: BABY, TEVA, EXEL, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "health care sector",
                    "update",
                    "BABY",
                    "TEVA",
                    "EXEL",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-14",
            "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2019",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "ex-dividend date",
                    "scheduled"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-14",
            "original_text": "Allergan plc. (AGN) Ex-Dividend Date Scheduled for February 14, 2019",
            "features": {
                "keywords": [
                    "Allergan",
                    "ex-dividend date",
                    "scheduled"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Pfizer and Eli Lilly: How Dividends and Tax Rates Stack Up",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eli Lilly",
                    "dividends",
                    "tax rates"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Pfizer or Eli Lilly: Who Is Controlling Expenses Better?",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eli Lilly",
                    "expenses",
                    "control"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Dogs of the Dow and a 3 Top Dogs Strategy",
            "features": {
                "keywords": [
                    "Dogs of the Dow",
                    "strategy",
                    "top dogs"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general market"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Bristol-Myers' Sprycel Gets European Nod for Label Expansion",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Sprycel",
                    "European nod",
                    "label expansion"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]